Awareness of potential drug interactions may aid avoidance.
DeVane
C L
CL
Gill
H S
HS
Markowitz
J S
JS
Carson
W H
WH
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000638:Amiodarone / Q000378:metabolism* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000378:metabolism* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000494:pharmacology*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003863:Depression / Q000188:drug therapy / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020280:Sertraline
D000889:Anti-Arrhythmia Agents; D000928:Antidepressive Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D015057:1-Naphthylamine; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D000638:Amiodarone; D020280:Sertraline